Tiziana Life Sciences Ltd Com Stock Price, News & Analysis

Tiziana Life Sciences (NASDAQ:TLSA) announced plans to advance TZLS-501, its fully human anti-IL-6 receptor monoclonal antibody. The decision follows Novartis' $1.4 billion acquisition of Tourmaline Bio, highlighting increased industry interest in IL-6 pathway therapeutics.

TZLS-501's dual mechanism of action targets both membrane-bound and soluble forms of IL-6R, blocking IL-6R signaling and reducing inflammatory cytokines. The company will pursue non-dilutive funding for TZLS-501's development while maintaining focus on its lead program, intranasal foralumab. The therapeutic shows potential for treating multiple conditions including rheumatoid arthritis, ARDS, pulmonary fibrosis, lupus, and various cancers.

Tiziana Life Sciences (NASDAQ:TLSA) announced its upcoming poster presentation at the 41st ECTRIMS Congress in Barcelona, Spain, from September 24-26, 2025. The presentation will focus on the Phase 2a clinical trial design for nasal foralumab, the first fully human anti-CD3 monoclonal antibody designed for intranasal delivery.

The study targets non-active secondary progressive multiple sclerosis patients, representing a novel approach to immune system modulation. The presentation, titled "Study Design of a Phase 2a Double-Blind Placebo-Controlled Trial of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis," will be showcased at ECTRIMS, the world's largest annual international conference for MS research.

Tiziana Life Sciences (NASDAQ:TLSA) has received a significant research grant from the U.S. Department of Defense to study intranasal anti-CD3 therapy for traumatic spinal cord injury (SCI). The company will conduct a three-year study focused on acute SCI treatment, complemented by a two-year Stepping Strong Breakthrough Award for chronic phase research.

The research targets a substantial market with 300,000 Americans living with permanent disability and 17,000 new cases annually. Preclinical results at Brigham and Women's Hospital have shown promising motor outcome improvements. The non-invasive intranasal delivery method aims to rebalance the immune system and reduce inflammation in injured spinal cords.

Tiziana Life Sciences (NASDAQ:TLSA), a biotechnology company focused on immunomodulation therapies, announced that CEO Ivor Elrifi has purchased 193,848 shares of company common stock at $1.65 per share in the open market. The company's lead development candidate is intranasal foralumab, a fully human anti-CD3 monoclonal antibody.

Tiziana Life Sciences (NASDAQ:TLSA), a biotechnology company focused on immunomodulation therapies, announced that its Executive Chairman and Founder Gabriele Cerrone has increased his stake in the company through a share purchase. Cerrone acquired 25,000 common shares at $1.60 per share, bringing his total holdings to 43,277,143 shares, representing 36.28% of the company's issued share capital.

Tiziana Life Sciences (NASDAQ:TLSA) has initiated dosing in its Phase 2a clinical trial of intranasal foralumab for Multiple System Atrophy (MSA) at Brigham and Women's Hospital in Boston. The six-month open-label study will evaluate foralumab's potential to reduce neuroinflammation in MSA patients through a novel nasal delivery system.

MSA is a rare neurodegenerative disorder affecting 15,000-50,000 people in the United States, with no FDA-approved treatments to alter disease progression. The trial (NCT06868628) will involve eight dosing cycles to assess the therapy's ability to slow disease progression and enhance quality of life through regulatory T cell engagement.

Tiziana Life Sciences (NASDAQ:TLSA) has received FDA approval for its Phase 2a Investigational New Drug (IND) application to study intranasal foralumab in Multiple System Atrophy (MSA) patients. The six-month, open-label clinical trial will evaluate foralumab, a fully human anti-CD3 monoclonal antibody, for its effects on microglial activation, clinical outcomes, and safety.

MSA is a rare, rapidly progressive neurodegenerative disorder with no FDA-approved treatments. The disease affects 1.9-4.9 per 100,000 people worldwide, with a median survival of 6-9 years. The trial (NCT06868628) will administer foralumab via nasal spray in eight 3-week dosing cycles, targeting T-cell mediated neuroinflammation.

Tiziana Life Sciences (NASDAQ:TLSA) has reported promising immunologic findings from treating a moderate Alzheimer's Disease patient with intranasal foralumab, their lead immunomodulation therapy. The analysis revealed significant immune modulatory effects in white blood cells, including changes in CD4 cells, CD8 cells, and monocytes.

Key findings include a marked reduction in brain inflammation confirmed by microglia PET scans and an unexpected increase in phagocytosis markers in classical monocytes, suggesting potential for enhanced amyloid plaque clearance. The treatment was well-tolerated with no side effects, and the patient will continue therapy for an additional 6 months.

Tiziana Life Sciences (NASDAQ: TLSA) has expanded its Phase 2 clinical trial of intranasal foralumab by initiating patient dosing at Weill Cornell Multiple Sclerosis Center, marking the fifth site in their study. The trial evaluates foralumab, a first-in-class fully human anti-CD3 monoclonal antibody, in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This site joins existing locations at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts. The study includes a six-month open-label extension phase following the blinded phase, allowing all participants to receive foralumab. The treatment's innovative intranasal delivery method aims to engage regulatory T cells and promote immune tolerance while minimizing systemic immune suppression.